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total number of patients with stable angina who have indications for ivabradine 
was 17559 people. The number of prevented cases of non-fatal myocardial infarc-
tion and unstable angina was 244 cases per year. The number of prevented cases 
of cardiovascular death was 95 cases per year. The number of prevented cases of 
surgical revascularization was 260 cases per year. ConClusions: The analysis 
allowed to identify Belarusian patients in need of ivabradine use by estimating 
the size of the target group of patients with stable angina and elevated heart 
rate for whom antianginal therapy is inadequate or impossible and who need an 
ivabradine prescription and potentially could make the most effective reaction 
to the therapy.
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objeCtives: Intermittent pneumatic compression (IPC) is proposed as an adjunct 
to medical care for people with critical limb ischemia (CLI) who are unsuitable for 
revascularisation. Given the lack of treatment options for these patients, a safe 
therapy that can be shown to provide even a modest clinical improvement may 
make a significant contribution to the management of this condition. This research 
aims to synthesise and critically appraise the evidence supporting the use of this 
technology in this cohort. Methods: A systematic review of the clinical effective-
ness of IPC in non-reconstructable CLI was performed. Medline, Embase and trial 
registries were searched for randomised controlled trials (RCTs), non-randomised 
controlled trials (nRCTs) and controlled before-and-after (CBA) studies compar-
ing IPC plus medical care to medical care only. Results: No RCTs or nRCTs were 
identified. Two CBA studies, both with a high risk of bias, found that IPC was asso-
ciated with improved limb salvage and wound healing (OR 7, 95% CI 1.82 to 26.89, 
p< 0.05 for both outcomes) as well as improved quality of life scores in bodily pain 
(mean difference [MD] 32.7, 95% CI 29.4 to 36.0, p< 0.05) and physical functioning 
(MD 18.8, 95% CI 14.1 to 23.6, p< 0.05). Improvements were also reported for initial 
and absolute claudication distances (MD 26.9m, 95% CI 21.7 to 32.1, p< 0.05; MD 
52.9m, 95% CI 42.2 to 63.6, p< 0.05, respectively). No serious adverse events were 
reported. ConClusions: Despite some promising results there is a lack of high-
quality evidence demonstrating the effectiveness of IPC in addition to medical 
management in non-reconstructable CLI. Where findings are equivocal a question 
arises as to the minimum level of evidence required to support the introduction of 
a technology when no effective alternatives exist. Competing interpretations of the 
balance of risks and benefits between different stakeholders in the decision-making 
process in these circumstances are discussed.
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objeCtives: To evaluate excess use of coronary angiography prior to coronary 
artery bypass graft (CABG) surgery and its association with mortality, health care 
costs and hospital quality in Turkey. Methods: MEDULA, a nationwide integrated 
system shared between general health insurance and health care providers in 
Turkey was used to analyze coronary angiography utilization. Patients age 18–99 
years who underwent CABG surgery between April 1, 2009 and October 1, 2010 were 
identified and assigned to “standard-therapy” or “excess-use” groups based on 
whether they had one or more coronary angiography, respectively, within 3 months 
of the first CABG diagnosis date (index date) during the identification period. 
Survival rates and annual health care costs of patients in the coronary angiog-
raphy standard-therapy and excess-use groups were compared using propensity 
score matching. The empirical Bayes approach was used to combine mortality 
and hospital volume for quality index. Chi-squared tests were used to assess the 
relationship between hospital quality and excess use of coronary angiography 
excess use. Results: From a total of 20,126 identified patients, 7.27% underwent 
excessive coronary angiography procedures, at average annual costs that were 
9.7% higher than patients with a single angiography (p< 0.01). Operational mortal-
ity associated with excessive use was significantly higher as well (7.4% vs. 5.4%, 
p< 0.02). Use of coronary angiography across cities and hospitals varied. Patients 
who underwent cardiac surgery in high-quality hospitals were less likely to have 
excessive angiography use than those in low-quality hospitals (7.0% vs. 9.5%, 
p< 0.01). ConClusions: In Turkey, excess use of coronary angiography prior to 
CABG surgery is associated with higher operational mortality, higher expenditures 
and lower hospital quality.
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objeCtives: To examined anticoagulant use and associated factors in hospitalized 
patients with acute venous thromboembolism (VTE) in the US clinical practice set-
ting. Methods: Adult VTE patients were selected from the linked MarketScan and 
Hospital Drug database in an inpatient setting between 07/01/2006-12/31/2011. The 
first hospitalization with a diagnosis of VTE was designated index hospitalization 
(IH). Patients were required to have at least 6 months continuous enrollment and 
dabigatran and rivaroxaban appear to have better safety and efficacy profiles when 
compared with warfarin. Apixaban and dabigatran 110mg consistently demon-
strated reduced risk of bleeding when compared with rivaroxaban and dabigatran 
150mg. Dabigatran150mg demonstrated increased efficacy on multiple endpoints 
when compared with rivaroxaban, while discontinuation rates were increased. 
Head-to-head studies would help clarify any differences among these medicines 
for efficacy and bleeding.
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objeCtives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was 
to conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. Methods: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: (1) a RCT in humans; (2) an investigation of 
patients with nonvalvular atrial fibrillation; (3) an evaluation of dabigatran com-
pared with warfarin or each other; and (4) a report of results of stroke or systemic 
emboli and major bleeding. A systematic literature search for dabigatran trials 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year and total 
bleeding events. For meta-analysis, random effects and fixed effects models were 
used to obtain cumulative statistics. Results: Two RCTs with a total of 12,268 
patients were identified. The pooled event rate for Dabigatran for total bleeding 
events was 31.9% (95% CI 31%-33%). The pooled response rate for Warfarin for 
total bleeding events was 35.1% (95% CI 34%-37%). The cumulative relative risk 
for total bleeding events with Dabigatran versus Warfarin was 0.91 (95% CI 0.89-
0.93) ConClusions: Meta-analysis shows Dabigatran has a slightly lower rate 
of total bleeding events compared to Warfarin.
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objeCtives: To evaluate efficacy/safety of ivabradine in chronic stable angina 
pectoris(CSAP) Thai patients. Methods: Ivabradine 5-7.5 mg bid was prescribed 
to CSAP patients. Hemodynamic parameters including systolic/diastolic blood 
pressure(SBP/DBP) in mmHg and heart rate(HR) in beats per minute(bpm) were 
recorded at entry and after 1,4 months follow-up. A standardized digital device 
was used to monitor BP and HR. Acceptability was evaluated in patient inter-
views. Results: A total of 256 patients, men/women ratio of 1.04, mean(SD) age 
67.1(12.4) years, 149(58%) were > 65 years old, 64(25%) and 76(29.7%) of patients 
had previous intervention and heart failure(HF). 127(50%)&51(20%) received beta-
blockers&nitrate as initial medication. Patients’ assessment was made using 
Canadian Cardiology Society angina pectoris classification(CCS). At entry, 34.9%, 
52.2% and 10.8% of patients were found with CCS grades 3, 2 and 1. Among 76 HF 
patients, 35.8%, 58.2% and 6.0% were found with stage 3, 2 and 1 of NYHA classifica-
tion. In overall population, mean(SD) baseline HR was 86.9(11.2) bpm and SBP/DBP 
137.8(24.6)/81.7(15.9) mmHg. After 4 months, mean(SD), HR significantly reduced to 
69.96(7.13)bpm (p< 0.001) and SBP/DBP lowered to 126.5(12.9)/73.9(8.9) mmHg, while 
mean arterial pressure(MAP)was optimally maintained at 100.4(17.6) mmHg. The 
highly significant drop in mean difference(SE) HR of 16.9(0.7) was observed with 
95% CI between 15.5-18.3 bpm. No significant mean difference(SE),[95% CI] SBP 
drop, between patients with/without HF, and with/without previous intervention 
of 7.32(1.17),[4.99-9.64] and 8.15(2.07),[4.02-12.2764], or 8.14(1.27),[5.61-10.67] and 
7.46(0.89),[5.69-9.22] (p= 0.502, p= 0.691) respectively. Improvement for CCS 3 and 
CCS 2 angina class, reduced to 1.9% and 36.1% whereas the NYHA classification 
for stage 3&2 reduced to 3.2%&56.4%(p< 0.001). Common AE reported were palpita-
tion(2.5%) and nausea(1%). ConClusions: Ivabradine is a well-tolerated heart rate 
reducing agent, effective for both chronic stable angina pectoris and heart failure. 
It effectively reduces elevated heart rate without affecting other hemodynamic 
parameters. In this Thai setting, ivabradine significantly improves CCS and NYHA 
classifications with minimal side effects being reported.
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objeCtives: To determine the potential population of patients with stable angina 
pectoris in Belarus who need prescription of ivabradine and setting the amount of 
the effect of the drug in this group of patients. Methods: In the research phar-
macoeconomic Markov model of ivabradine application in patients with stable 
angina, national surveillance data, analysis of literature have been used. Patients 
with stable angina after revascularization, patients with contraindications to 
beta-blocker use, not applying the dihydropyridines and having a contraindica-
tion to ivabradine use have been used to determine the target population. The 
number of prevented or postponed events – PPE - (nonfatal myocardial infarction 
and unstable angina, cardiovascular death, the number of surgical revasculariza-
tion) has been calculated. For the potential efficacy of ivabradine use in patients 
with stable angina and heart rate ≥ 70 bpm calculating the data about efficacy in 
accordance with the results of the Beautiful study were used Results: The total 
number of patients with stable angina pectoris in Belarus in 2011 was 242943. The 
